Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

IL-6 increases SDCBP expression, cell proliferation, and cell invasion by activating JAK2/STAT3 in human glioma cells.

Cao F, Zhang Q, Chen W, Han C, He Y, Ran Q, Yao S.

Am J Transl Res. 2017 Oct 15;9(10):4617-4626. eCollection 2017.

2.

Butyltin compounds alter secretion of interleukin 6 from human immune cells.

Brown S, Wilburn W, Martin T, Whalen M.

J Appl Toxicol. 2018 Feb;38(2):201-218. doi: 10.1002/jat.3514. Epub 2017 Aug 24.

PMID:
28840599
3.

Morita-Baylis-Hillman Adducts Display Anti-Inflammatory Effects by Modulating Inflammatory Mediator Expression in RAW264.7 Cells.

Faheina-Martins GV, Leite JA, Dantas BB, Lima-Júnior CG, Vasconcellos MLAA, Rodrigues-Mascarenhas S, Araújo DAM.

Mediators Inflamm. 2017;2017:6898505. doi: 10.1155/2017/6898505. Epub 2017 Jul 12.

4.

Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression.

Takada K, Okamoto T, Tominaga M, Teraishi K, Akamine T, Takamori S, Katsura M, Toyokawa G, Shoji F, Okamoto M, Oda Y, Hoshino T, Maehara Y.

PLoS One. 2017 Jul 20;12(7):e0181598. doi: 10.1371/journal.pone.0181598. eCollection 2017.

5.

Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.

Bollino D, Webb TJ.

Transl Res. 2017 Sep;187:32-43. doi: 10.1016/j.trsl.2017.06.003. Epub 2017 Jun 9. Review.

PMID:
28651074
6.

Interleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target.

Tvedt THA, Ersvaer E, Tveita AA, Bruserud Ø.

Front Immunol. 2017 Jun 8;8:667. doi: 10.3389/fimmu.2017.00667. eCollection 2017. Review.

7.

Autocrine Loop Involving IL-6 Family Member LIF, LIF Receptor, and STAT4 Drives Sustained Fibroblast Production of Inflammatory Mediators.

Nguyen HN, Noss EH, Mizoguchi F, Huppertz C, Wei KS, Watts GFM, Brenner MB.

Immunity. 2017 Feb 21;46(2):220-232. doi: 10.1016/j.immuni.2017.01.004.

PMID:
28228280
8.

Multiple functional SNPs in differentially expressed genes modify risk and survival of non-small cell lung cancer in Chinese female non-smokers.

Fang X, Yin Z, Li X, Xia L, Quan X, Zhao Y, Zhou B.

Oncotarget. 2017 Mar 21;8(12):18924-18934. doi: 10.18632/oncotarget.14836.

9.

Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy.

Feng T, Cao W, Shen W, Zhang L, Gu X, Guo Y, Tsai HI, Liu X, Li J, Zhang J, Li S, Wu F, Liu Y.

Oncotarget. 2017 Jan 3;8(1):329-344. doi: 10.18632/oncotarget.13393.

10.

Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis.

Lippitz BE, Harris RA.

Oncoimmunology. 2016 May 11;5(5):e1093722. doi: 10.1080/2162402X.2015.1093722. eCollection 2016 May. Review.

11.

p70S6K promotes IL-6-induced epithelial-mesenchymal transition and metastasis of head and neck squamous cell carcinoma.

Wu D, Cheng J, Sun G, Wu S, Li M, Gao Z, Zhai S, Li P, Su D, Wang X.

Oncotarget. 2016 Jun 14;7(24):36539-36550. doi: 10.18632/oncotarget.9282.

12.

Treatment with anti-IL-6 receptor antibody prevented increase in serum hepcidin levels and improved anemia in mice inoculated with IL-6-producing lung carcinoma cells.

Noguchi-Sasaki M, Sasaki Y, Shimonaka Y, Mori K, Fujimoto-Ouchi K.

BMC Cancer. 2016 Apr 11;16:270. doi: 10.1186/s12885-016-2305-2.

13.

MiR-26 down-regulates TNF-α/NF-κB signalling and IL-6 expression by silencing HMGA1 and MALT1.

Chen CY, Chang JT, Ho YF, Shyu AB.

Nucleic Acids Res. 2016 May 5;44(8):3772-87. doi: 10.1093/nar/gkw205. Epub 2016 Mar 28.

14.

IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3.

Desai A, Jung MY, Olivera A, Gilfillan AM, Prussin C, Kirshenbaum AS, Beaven MA, Metcalfe DD.

J Allergy Clin Immunol. 2016 Jun;137(6):1863-1871.e6. doi: 10.1016/j.jaci.2015.09.059. Epub 2016 Jan 7.

15.

Interleukin 6 trigged ataxia-telangiectasia mutated activation facilitates lung cancer metastasis via MMP-3/MMP-13 up-regulation.

Jiang YN, Yan HQ, Huang XB, Wang YN, Li Q, Gao FG.

Oncotarget. 2015 Dec 1;6(38):40719-33. doi: 10.18632/oncotarget.5825.

16.

HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines.

Johnston PA, Sen M, Hua Y, Camarco DP, Shun TY, Lazo JS, Wilson GM, Resnick LO, LaPorte MG, Wipf P, Huryn DM, Grandis JR.

Assay Drug Dev Technol. 2015 Sep;13(7):356-76. doi: 10.1089/adt.2015.663.

17.

Modification of Gene Expression, Proliferation, and Function of OP9 Stroma Cells by Bcr-Abl-Expressing Leukemia Cells.

Supper E, Tahir S, Imai T, Inoue J, Minato N.

PLoS One. 2015 Jul 28;10(7):e0134026. doi: 10.1371/journal.pone.0134026. eCollection 2015.

18.

Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.

Cao W, Liu Y, Zhang R, Zhang B, Wang T, Zhu X, Mei L, Chen H, Zhang H, Ming P, Huang L.

Sci Rep. 2015 Jul 13;5:8477. doi: 10.1038/srep08477.

19.

Association of interleukin-6 polymorphisms with susceptibility to hepatocellular carcinoma.

Zheng X, Han C, Shan R, Zhang H, Zheng Z, Liu Y, Wang A.

Int J Clin Exp Med. 2015 Apr 15;8(4):6252-6. eCollection 2015.

20.

Interleukin-6 Prevents the Initiation but Enhances the Progression of Lung Cancer.

Qu Z, Sun F, Zhou J, Li L, Shapiro SD, Xiao G.

Cancer Res. 2015 Aug 15;75(16):3209-15. doi: 10.1158/0008-5472.CAN-14-3042. Epub 2015 Jun 29.

Supplemental Content

Support Center